AbbVie loses bid to hoard documents in Humira patent fight with Boehringer

Boehringer Ingelheim is one of the only—if not the only—biosimilar maker still challenging AbbVie’s Humira patents in court. And the German drugmaker just won a skirmish in that high-stakes battle, gaining access to documents AbbVie had fought to keep secret.